Understanding FCGR1BP: A Potential Drug Target Or Biomarker (G2210)

Target Name: FCGR1BP

NCBI ID: G2210

Understanding FCGR1BP: A Potential Drug Target Or Biomarker

FCGR1BP (CD64), a cell surface protein expressed in most tissues of the body, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure, localization, and regulation make it an attractive target for small molecule inhibitors.

FCGR1BP is a 18-kDa transmembrane protein that is expressed in various tissues, including the brain, heart, liver, and spleen. It is highly expressed in fetal tissues and has been suggested to play a role in fetal development and maintenance. FCGR1BP has been shown to localize to the endoplasmic reticulum (ER) and to be involved in the regulation of cellular processes, including cell adhesion, migration, and survival.

The potential drug targets for FCGR1BP are numerous and varied. Its localization to the ER and its involvement in cell adhesion processes make it a potential target for small molecule inhibitors that can modulate endoplasmic reticulum-associated signaling pathways. Additionally, its role in cell migration and survival make it a potential target for inhibitors that can modulate the pro-migratory signaling pathways that drive cancer cell growth and metastasis.

FCGR1BP has also been shown to be involved in the regulation of cellular interactions with the immune system. Its localization to the endoplasmic reticulum and its involvement in the regulation of apoptosis make it a potential target for small molecule inhibitors that can modulate T cell function and immune surveillance.

In neurodegenerative diseases, FCGR1BP has been suggested to play a role in the regulation of neurotransmitter signaling and in the maintenance of cellular processes that are critical for brain function. Its localization to the ER and its involvement in the regulation of neurotransmitter release have led to the hypothesis that it may be a potential target for small molecule inhibitors that can modulate neurotransmitter signaling pathways and improve neurodegenerative disease management.

In autoimmune disorders, FCGR1BP has been suggested to play a role in the regulation of immune cell function and in the development of autoimmune diseases. Its localization to the ER and its involvement in the regulation of apoptosis have led to the hypothesis that it may be a potential target for small molecule inhibitors that can modulate immune cell function and improve autoimmune disease management.

In conclusion, FCGR1BP is a promising drug target or biomarker due to its unique localization, regulation, and involvement in various cellular processes. Its potential as a drug target or biomarker makes it an attractive target for small molecule inhibitors that can modulate endoplasmic reticulum-associated signaling pathways, pro-migratory signaling pathways, neurotransmitter signaling pathways, and immune cell function. Further research is needed to fully understand the role of FCGR1BP as a drug target or biomarker and to develop effective small molecule inhibitors that can modulate its function.

Protein Name: Fc Gamma Receptor Ib, Pseudogene

Functions: May bind to the Fc region of immunoglobulins gamma with a low affinity compared to FCGR1A. May function in the humoral immune response

More Common Targets